TJ191

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

TJ191是一种选择性抗癌化合物，针对低TβRIII表达的恶性T细胞白血病/淋巴瘤细胞。

TJ191 is a selective anti-cancer agent, targeting low TβRIII-expressing malignant T-cell leukemia/lymphoma cells.

TJ191(0-100 μM; 24 hours) exhibits pronounced anti-proliferative activity in malignant?cell?lines, the IC50 values are 0.13 μM, 0.13±0.08 μM, 0.26±0.19 μM, 0.22±0.11 μM, 1.5±0.02 μM, 0.32±0.086 μM, 3.1±0.5 μM, 0.26±0.16 μM in CEM, JURKAT, MOLT-3, MOLT-4, SUP-T1, MT-2, C8166 and HSB-2 cells, respectively. But has no effects in HUT-78 (IC50=17±10 μM) and MT-4 (IC50=47 ± 5 μM) cells.TJ191 (0.1-3 μM; 8 or 24 hours) induces CEM cell apoptosis in a concentration- and time-dependent manner. Even at 0.3 μM, TJ191 induces the maximum apoptotic rate of 80% after 24 h. Cell Viability Assay Cell Line:Malignant T-cell leukemia/lymphoma cells Concentration:0.01 μM, 0.1 μM, 1 μM, 10 μM, 100 μM Incubation Time:24 hours Result:Exhibited inhibitory effects in drug-sensitive cells with IC50 ranging 0.13 μM to 3.1 μM. Apoptosis Analysis Cell Line:CEM cell line Concentration:0.1-3 μM Incubation Time:8 or 24 hoursResult:Led to cell apoptosis.

——

——

Apoptosis

Apoptosis

Apoptosis

——

——

1522415-97-9

255.38

C13H21NO2S

>98% (HPLC)

DMSO:10 mM

CCCCCCCC1=CC(C(OC)=O)=C(N)S1

——

(-20℃)

With Ice Pack

≥ 2 years